I keep buying at these lows. Hard to believe it was in the 2.30;s recently, and still low volume. 2B only months away.
m
Loading up. This is too cheap and could be a 12x on 2B
m
Folks. 2B is all that matters. Expect muted movement until 2B results are released. Could get a grant which would likely provide a good move but stil.. 2B. All that matters
g
Buying more
B
Somebody wanted out today. Why sell at a low?
L
Margin call?
b
Finally some good signs, with the stock price going from 3.11, to $4 Thursday. a lot of big buys this week had the stock moving nicely. Looking for some info comming in next week
D
I just bought 1.5k should i worry?
M
Incredible P2A data - patients have been 100% cured with no recurrence of CDI. P2b data should confirm and launch this thing to the moon. I got in pre-IPO and really like the odds here.
m
Summit didn’t meet their phase 3 endpoint. Summit was ACXP’s primary competition. Let the buss begin!
m
$20+ in 8 months or less $50+ in 18 months
Total hidden gem
W
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference
See Yahoo headline
a
Stock will be over $25 on good phase 2B data.
D
I'm in. Sounds like a winner.
D
Is there always a Phase 2b before going on to Phase 3? I don't recall this with other bio's that I've owned. Regardless, good news this AM.
D
Appears good price entry IPO
D
Here we go. Antibiotics are "easy" FDA approval. New class, targeting resistant bacteria.
m
-100% cure. 0% recurrence. Way better than vanco. Way better than summit. -30% insider ownership -continual insider buying -500M sales at only 20% market penetration -most compelling pick according to biopub -pasteur act potential -best medical advisor board -restores microbiome unlike any other option -amr fund potential - Novo nordisk fund potential -icing in the cake is 1B sales on their clinical stage acx-375 if approved and achieves only 4% penetration
If they are front line drug for cdiff and have a ps ratio of 4 that implies a market cap of 6B. Which would be a 125x upside
125x plus whatever they get from axc-375
D
Insiders acquired a ton of shares at month end. Very good news.
$50+ in 18 months
Total hidden gem
See Yahoo headline
-30% insider ownership
-continual insider buying
-500M sales at only 20% market penetration
-most compelling pick according to biopub
-pasteur act potential
-best medical advisor board
-restores microbiome unlike any other option
-amr fund potential
- Novo nordisk fund potential
-icing in the cake is 1B sales on their clinical stage acx-375 if approved and achieves only 4% penetration
If they are front line drug for cdiff and have a ps ratio of 4 that implies a market cap of 6B. Which would be a 125x upside
125x plus whatever they get from axc-375